Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Sell at Wall Street Zen

Key Points

• Wall Street Zen upgraded Recursion Pharmaceuticals from “strong sell” to “sell,” while analysts overall maintain a consensus “Hold” rating with an $8.06 price target.
• Recursion’s latest quarterly results fell short of expectations, reporting a $0.25-per-share loss and $7.67 million in revenue versus estimates of a $0.24 loss and $10.97 million in revenue.
• RXRX shares opened at $3.34, near their 50-day and 200-day moving averages, and the company has a market capitalization of approximately $1.79 billion. Insiders sold 131,937 shares worth about $478,874 over the past three months.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued on Saturday.

A number of other research firms have also recently commented on RXRX. Needham & Company LLC reissued a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Finally, Morgan Stanley set a $5.30 price target on shares of Recursion Pharmaceuticals in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Recursion Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $8.06.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX opened at $3.34 on Friday. The company has a market cap of $1.79 billion, a P/E ratio of -3.21 and a beta of 1.03. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03. Recursion Pharmaceuticals has a one year low of $2.77 and a one year high of $7.18. The business's 50-day simple moving average is $3.32 and its 200 day simple moving average is $3.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The company had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period last year, the firm posted ($0.41) earnings per share. On average, sell-side analysts forecast that Recursion Pharmaceuticals will post -0.92 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 40,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $3.96, for a total transaction of $158,400.00. Following the completion of the sale, the director owned 6,218,287 shares in the company, valued at $24,624,416.52. This trade represents a 0.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $3.58, for a total value of $84,445.04. Following the sale, the chief executive officer owned 2,175,796 shares of the company's stock, valued at approximately $7,789,349.68. This trade represents a 1.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 131,937 shares of company stock valued at $478,874 in the last three months. 6.65% of the stock is currently owned by company insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC acquired a new stake in Recursion Pharmaceuticals in the fourth quarter valued at $31,000. Integral Investment Advisors Inc. bought a new position in Recursion Pharmaceuticals during the 1st quarter valued at $39,000. Sequoia Financial Advisors LLC acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth $41,000. MQS Management LLC acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth $41,000. Finally, Fund Advisors of America Inc FL bought a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth about $45,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc NASDAQ: RXRX is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source